The FTO inhibitor R-2-hydroxyglutarate (R-2HG) displays anti-tumor activity in non-IDH mutant AML and glioma by targeting FTO/m6A/MYC/CEBPA signaling [110]. The gene discussed is MYC; the disease is acute myeloid leukemia.